Implantation of a second closure device in patients with residual shunt after percutaneous closure of patent foramen ovale
โ Scribed by Markus Schwerzmann; Stephan Windecker; Andreas Wahl; Krassen Nedeltchev; Heinrich P. Mattle; Christian Seiler; Bernhard Meier
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- English
- Weight
- 230 KB
- Volume
- 63
- Category
- Article
- ISSN
- 1522-1946
No coin nor oath required. For personal study only.
โฆ Synopsis
Abstract
Percutaneous closure of patent foramen ovale (PFO) in patients with presumed paradoxical embolism yields complete occlusion in > 90% of patients using contemporary closure devices. Patients with a residual shunt after percutaneous PFO closure have been found at increased risk for recurrent paradoxical events. Treatment options for such patients include medical treatment using antiplatelet drugs or oral anticoagulation, surgical device removal and patch closure, and percutaneous implantation of a second closure device. We report our experience with implantation of a second closure device in 10 patients with more than a minimal residual shunt โค 6 months after percutaneous PFO closure. Procedure and fluoroscopy times were similar for the initial and repeat intervention (32 vs. 30 min and 5 vs. 6 min, respectively; P = NS). There were no procedural complications during implantation of the second closure device. Followโup transesophageal echocardiography 6 months after the second percutaneous intervention revealed complete PFO closure in nine (90%) patients. Therefore, implantation of a second closure device in patients with persistence of more than a residual shunt after percutaneous PFO closure appears safe and effective. Catheter Cardiovasc Interv 2004;63:490โ495. ยฉ 2004 WileyโLiss, Inc.
๐ SIMILAR VOLUMES
## Abstract ## Background: Percutaneous closure of patent foramen ovale (PFO) is routinely performed with nonbiological devices, characterized by a persistent lowโgrade inflammatory response. We report our experience about PFO closure with a bioabsorbable device, BioSTARยฎ (NMT Inc, USA). ## Metho
## Abstract Background: Moderateโtoโlarge residual shunts following percutaneous patent foramen ovale (PFO) closure are clinically important and associated with recurrent neuroembolic events. However, their management has not been clearly established in clinical practice. We report our experience i